Alpine Global Management’s Iterum Therapeutics ITRM Stock Holding History

Alpine Global Management’s Portfolio ITRM Stock Details ITRM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-10,000	Closed	-$6.7K	–	387
2025 Q3	$6.7K	Hold	10,000	–	–	﹤0.01%	202
2025 Q2	$9.95K	Hold	10,000	–	–	﹤0.01%	156
2025 Q1	$12.3K	Sell	10,000 -5,000	-33%	-$7.42K	﹤0.01%	126
2024 Q4	$26.6K	Sell	15,000 -49,833	-77%	-$78.1K	0.01%	164
2024 Q3	$70.7K	Buy	+64,833	New	+$77.1K	0.02%	147

Other funds holding ITRM

Apollon Financial Mount Pleasant, South Carolina $848M AUM 27.31% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Alchemi Wealth Essex, Connecticut $213M AUM

CAPTRUST Financial Advisors Raleigh, North Carolina $65.5B AUM 24.25% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

GWP

Gen-Wealth Partners Zeeland, Michigan $360M AUM 27.44% 1-Year Est. Return

Krilogy Financial St. Louis, Missouri $3.38B AUM 30.57% 1-Year Est. Return

Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return

GSC

Ground Swell Capital Folly Beach, South Carolina $92.6M AUM 41.64% 1-Year Est. Return

Sanctuary Advisors Indianapolis, Indiana $21.6B AUM 28.31% 1-Year Est. Return

Alpine Global Management's ITRM Position: Q4 2025 in Review

Alpine Global Management sold out of Iterum Therapeutics (ITRM) in Q4 2025, closing a stake of 10,000 shares — an estimated $6.7K sold.

Alpine Global Management first reported a position in ITRM in Q3 2024 and held it in 5 quarters. The position peaked at $70.7K in Q3 2024. 20 funds tracked by Wall St. Rank hold ITRM as of Q4 2025.

Alpine Global Management reported no remaining Iterum Therapeutics position as of Q4 2025 after selling out during the quarter.
Alpine Global Management sold 10,000 Iterum Therapeutics shares in Q4 2025, an estimated $6.7K.
Alpine Global Management first reported a position in Iterum Therapeutics in Q3 2024 and held it in 5 quarters.
Alpine Global Management's Iterum Therapeutics position peaked at $70.7K in Q3 2024.
20 funds tracked by Wall St. Rank held Iterum Therapeutics as of Q4 2025.

Based on Alpine Global Management's 13F filing for Q4 2025, filed 17 Feb 2026.